Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
In this open-label, randomized, prospective clinical trial, newly-diagnosed AML patients will
be randomized into 2 groups. In the experimental arm, patients receive DA induction regimen
with intermediate dose of cytarabine. In the control arm, patients receive DA regimen with
standard dose of cytarabine.The efficacy of induction therapy containing intermediate dose of
cytarabine is evaluated and adverse events associated with treatment are recorded.The primary
end point is overall survival.